Literature DB >> 10450686

Implications of nonuniform tumor doses for radioimmunotherapy.

J A O'Donoghue1.   

Abstract

UNLABELLED: This article describes a method of assessing the biologic consequences of nonuniform dose distributions produced in tumors by biologically targeted radionuclide therapy. The analysis is based on a simple mathematical model that assumes all tumor cells are uniformly radiosensitive.
METHODS: Using the linear-quadratic radiobiologic model, it is possible to represent an absorbed dose distribution by a biologically effective dose (BED) volume histogram (BVH). The Laplace transform of the BVH yields an equivalent uniform biologically effective dose. This is a one-number value that fully describes the biologic effect of a nonuniform absorbed dose distribution. In this article, for the purposes of exposition, nonuniform BED distributions are represented by normal distributions.
RESULTS: Nonuniform absorbed dose distributions are inefficient in sterilizing tumors and become proportionately less effective as the mean dose increases. The loss in effectiveness is most severe for radiosensitive tumors.
CONCLUSION: Several approaches may alleviate the consequences of dosimetric nonuniformity. These include the use of smaller targeting molecules, radionuclides with longer emission ranges, fractionated administration of biologically targeted radionuclide therapy and combined modality treatments.

Entities:  

Mesh:

Year:  1999        PMID: 10450686

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

1.  When may a nonuniform distribution of 131I be considered uniform? An experimental basis for multicellular dosimetry.

Authors:  Prasad V S V Neti; Roger W Howell
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

2.  A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Authors:  John M Akudugu; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-04-14       Impact factor: 2.408

3.  Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Authors:  Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

4.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

Review 5.  Clinical radioimmunotherapy--the role of radiobiology.

Authors:  Jean-Pierre Pouget; Isabelle Navarro-Teulon; Manuel Bardiès; Nicolas Chouin; Guillaume Cartron; André Pèlegrin; David Azria
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

6.  Biological response to nonuniform distributions of (210)Po in multicellular clusters.

Authors:  Prasad V S V Neti; Roger W Howell
Journal:  Radiat Res       Date:  2007-09       Impact factor: 2.841

7.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

Review 8.  Preclinical animal research on therapy dosimetry with dual isotopes.

Authors:  Mark W Konijnenberg; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-01       Impact factor: 9.236

Review 9.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

10.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.